ACE inhibitors, hyperkalemia ---> SmPC of [imidapril] of eMC
ACE inhibitors must not be associated with hyperkalemic substances, except in hypokalemia.
AIIRA, hyperkalemia
The combination may lead to hyperkalemia. Co-administration is not recommended
Aliskiren [1], hyperkalemia ---> SmPC of [1] of EMA
Concomitant use of other agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium levels may lead to increases in serum potassium.
Aliskiren/amlodipine/hydrochlorothiazide [1], hyperkalemia ---> SmPC of [1] of EMA
Concomitant use of aliskiren with other agents that increase serum potassium levels may lead to increases in serum potassium. If co-medication is considered necessary, caution is advisable.
Amlodipine/valsartan [1], hyperkalemia ---> SmPC of [1] of EMA
If a medicinal product that affects potassium levels is to be prescribed in combination with valsartan, monitoring of potassium plasma levels is advised.
Amlodipine/valsartan/hydrochlorothiazide [1], hyperkalemia ---> SmPC of [1] of EMA
If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.
Azilsartan medoxomil [1], hyperkalemia ---> SmPC of [1] of EMA
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of serum potassium should be undertaken as appropriate
Azilsartan [1], hyperkalemia ---> SmPC of [1] of EMA
The combination may lead to hyperkalemia. Co-administration is not recommended
Bemiparin, hyperkalemia
Medicinal products that increase the serum potassium concentration should only be taken concomitantly under especially careful medical supervision
Benazepril, hyperkalemia
Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.
Captopril [1], hyperkalemia ---> SmPC of [1] of eMC
Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Cardiac glycosides, hyperkalemia
The increase of extracellular potasium concentrations decreases the effect of the cardiac glycoside
Certoparin, hyperkalemia
Increased risk of hyperkalemia, particularly in renal failure
Cilazapril [1], hyperkalemia ---> SmPC of [1] of eMC
Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Cotrimoxazole, hyperkalemia
Caution is recommended when receiving other drugs that may cause hyperkaliemia
Cyclosporine [1], hyperkalemia ---> SmPC of [1] of eMC
Caution is required with concomitant use of ciclosporin with potassium-sparing medicinal products or potassium-containing medicinal products since they may lead to significant increases in serum potassium
Dalteparin, hyperkalemia
The co-administration of dalteparin with medicinal drugs which increase the serum potassium should be done with special care
Delapril, hyperkalemia
Increased risk of hyperkalemia, particularly in renal failure
Dexibuprofen [1], hyperkalemia ---> SmPC of [1] of eMC
As with other NSAIDs, concomitant treatment with drugs increasing potassium plasma levels, may be associated with increased serum potassium levels and may increase the risk of renal failure
Digitoxin, hyperkalemia
The co-administration may decrease the positive inotrope effect of digitoxin and promote heart rhythm disorders
Digoxin, hyperkalemia
The co-administration may decrease the positive inotrope effect of digoxin and promote heart rhythm disorders
Drospirenone, hyperkalemia
Increased risk of hypercaliemia
Enalapril/hydrochlorothiazide [1], hyperkalemia ---> SmPC of [1] of eMC
ACE inhibitors attenuate diuretic induced potassium loss. Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Enoxaparin sodium [1], hyperkalemia ---> SmPC of [1] of EMA
Medicinal products that increase serum potassium levels may be administered concurrently with enoxaparin sodium under careful clinical and laboratory monitoring
Enoxaparin, hyperkalemia
Medicinal products that increase the serum potassium level may only be used concurrently with enoxaparin under careful monitoring
Eprosartan [1], hyperkalemia ---> SmPC of [1] of eMC
Concomitant use of eprosartan with K-sparing diuretics, K-supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increase in serum potassium.
Flecainide [1], hyperkalemia ---> SmPC of [1] of eMC
Hypokalaemia but also hyperkalaemia or other electrolyte disturbances should be corrected before administration of flecainide. Hypokalaemia may result from the concomitant use of diuretics, corticosteroids or laxatives.
Fosinopril [1], hyperkalemia ---> SmPC of [1] of eMC
Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.
Heparin, hyperkalemia ---> SmPC of [sodium heparin] of eMC
Medicinal products that increase potassium plasma concentrations, like heparine, should only be used under especially careful medical supervision
Hyperkalemia, hyperkalemia
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, imidapril [2] ---> SmPC of [2] of eMC
ACE inhibitors must not be associated with hyperkalemic substances, except in hypokalemia.
Hyperkalemia, irbesartan [2] ---> SmPC of [2] of EMA
Concomitant use of irbesartan und potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels is not recommended
Hyperkalemia, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, lisinopril [2] ---> SmPC of [2] of eMC
The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes, particularly in patients with impaired renal function, may lead to a significant increase in serum potassium.
Hyperkalemia, losartan [2] ---> SmPC of [2] of eMC
Concomitant use of other drugs which retain potassium or may increase potassium levels, potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium. Co-medication is not advisable.
Hyperkalemia, metildigoxin
Effect weakening of metildigoxin
Hyperkalemia, moexipril
Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.
Hyperkalemia, nabumetone
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, nadroparin
The use of heparin may inhibit the adrenal secretion of aldosterone giving rise to hypercaliemia, in particular if patients are taking drugs that may cause hypercaliemia
Hyperkalemia, naproxen
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, NSAID ---> SmPC of [dexibuprofen] of eMC
As with other NSAIDs, concomitant treatment with drugs increasing potassium plasma levels, may be associated with increased serum potassium levels and may increase the risk of renal failure
Hyperkalemia, olmesartan
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.
Hyperkalemia, olmesartan medoxomil [2] ---> SmPC of [2] of eMC
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.
Hyperkalemia, olmesartan medoxomil/amlodipine [2] ---> SmPC of [2] of eMC
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.
Hyperkalemia, perindopril [2] ---> SmPC of [2] of eMC
The combination of these drugs increases the risk of hyperkalaemia.
Hyperkalemia, piroxicam
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, potassium canrenoate
The co-administration may cause hyperpotassemia und is not recommended
Hyperkalemia, potassium citrate/potassium hydrogen carbonate [2] ---> SmPC of [2] of EMA
Concomitant use of Sibnayal with medicinal products that may increase potassium levels or induce hyperkalaemia necessitates monitoring of potassium plasma levels
Hyperkalemia, potassium iodide [2] ---> SmPC of [2] of eMC
Drugs-induced hyperkalaemia may be enhanced if potassium iodide is also administered
Hyperkalemia, potassium-sparing diuretics
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, quinapril [2] ---> SmPC of [2] of eMC
Concomitant treatments of quinapril with potassium sparing diuretics, potassium supplements or potassium salts should be used with caution and with appropriate monitoring of serum potassium.
Hyperkalemia, ramipril [2] ---> SmPC of [2] of eMC
Hyperkalaemia may occur, therefore close monitoring of serum potassium is required. Caution is recommended
Hyperkalemia, reviparin
Caution is recommended when coadministering reviparin with drugs that increase plasma potassium levels
Hyperkalemia, sodium heparin
Medicinal products that increase potassium plasma concentrations, like heparine, should only be used under especially careful medical supervision
Hyperkalemia, spirapril
Increased risk of hyperkalemia, particularly in renal failure
Hyperkalemia, spironolactone [2] ---> SmPC of [2] of eMC
The co-administration may cause severe hyperkalaemia
Hyperkalemia, tacrolimus [2] ---> SmPC of [2] of EMA
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics should be avoided
Hyperkalemia, telmisartan [2] ---> SmPC of [2] of EMA
As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia. The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia
Hyperkalemia, telmisartan/amlodipine ---> SmPC of [telmisartan] of EMA
As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia. The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia
Hyperkalemia, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
Medicinal products that may increase potassium levels or induce hyperkalaemia: Concomitant use of the these medicinal products may lead to increases in serum potassium and is, therefore, not recommended
Hyperkalemia, tinzaparin
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, trandolapril
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, trandolapril/verapamil [2] ---> SmPC of [2] of eMC
Potassium supplements or potassium sparing diuretics are generally not recommended, since they may lead to significant increases in plasma potassium.
Hyperkalemia, trimethoprim
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
Hyperkalemia, valsartan ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.